A peripherally inserted central catheter is a safe means of ensuring long-term central venous access in patients with acute leukaemia – a single centre experience
Authors:
T. Szotkowski 1; M. Čerňan 1; L. Vráblová 1; P. Rohoň 2; V. Hájková 1; P. Holúbková 1; K. Kaštilová 1; P. Konupčíková 1; K. Kovaříková 1; S. Utíkalová 1; H. Vašková 1; M. Vodičková 1; J. Vykydalová 1; M. Labudíková 1; T. Papajík 1
Authors‘ workplace:
Hemato-onkologická klinika LF UP a FN Olomouc
1; Klinika hematológie a transfuziológie LF UK, SZU a UNB Bratislava
2
Published in:
Transfuze Hematol. dnes,1, 2020, No. Preview preliminary publication, p. 1-17.
Category:
Overview
A peripherally inserted central catheter (PICC) is one of the available options of medium or long-term central venous system access. The aim of this paper is to demonstrate the experience of the Department of Haemato-Oncology in Olomouc with implantation and use of PICCs in patients with acute leukaemia.
Between 2016–2020, a total of 94 catheters was inserted by our own team in 79 patients with acute leukaemia. These included 71 patients with acute myeloid leukaemia and 8 patients with acute lymphoblastic leukaemia; 41 women and 38 men with an average age of 51 years. Sixty-eight patients were treated with curative intent, 11 were primarily treated palliatively. The patients most often received a double lumen PICC with a diameter of 5 Fr (French) - 61 cases- and 29 catheters were single lumen with a diameter of 4 Fr, In 4 cases a triple lumen 6 Fr catheter was inserted. On average, catheters remained in situ for 156 days. The total duration of PICC insertion in patients with acute leukaemia by November 30th 2020 was 14,420 catheter days.
By this date, 76 catheters had been extracted, in most cases because of treatment discontinuation – 28 cases (36.8 %). We recorded six thrombotic complications. Four cases of inflammation at the catheter entry site and 3 complete obturations required catheter extraction. There was no case of bacteraemia demonstrably associated with the catheter.
In our opinion, the use of PICCs in patients with acute leukaemia is a suitable and safe alternative to centrally inserted central catheters when a stable venous access is required.
Keywords:
venous access – PICC – acute leukaemia
Sources
- Maňásek V, Charvát J. Periferní centrální žilní katétry. In Charvát J a kolektiv. Žilní vstupy. 1. vyd. Praha, Grada Publishing, 2016;100–121.
- Maňásek V, Soumarová R, Kociánová I, Maňásková M. Žilní vstupy v onkologii. Klin Onkol. 2012;25(1):9–16.
- Kabut T, Weinbergerová B, Kocmanová I, et al. Použití a infekce centrálních venózních katetrů u hematologických pacientů: situace v České republice a na Slovensku a doporučení v jejich prevenci a diagnostice. Transfuze Hematol Dnes. 2018;24(1):27–36.
- Strahilevitz J, Lossos IS, Verstandig A, Sasson T, Kori Y, Gillis S. Vascular access via peripherally inserted central venous catheters (PICCs): experience in 40 patients with acute myeloid leukemia at a single institute. Leuk Lymphoma. 2001;40(3–4):365–371.
- Refaei M, Fernandes B, Brandwein J, Goodyear MD, Pokhrel A, Wu C. Incidence of catheter-related thrombosis in acute leukemia patients: a comparative, retrospective study of the safety of peripherally inserted vs. centrally inserted central venous catheters. Ann Hematol. 2016;95:2057–2064.
- Chen MH, Hwang WL, Chang KH, Chiang LCJ, Teng CLJ. Application of peripherally inserted central catheter in acute myeloid leukaemia patients undergoing induction chemotherapy. Eur J Cancer Care. 2017;26(6):e12627.
- Picardi M, Pepa RD, Cerchione C, et al. A frontline approach with peripherally inserted versus centrally inserted central venous catheters for remission induction chemotherapy phase of acute myeloid leukemia: a randomized comparison. Clin Lymphoma Myeloma Leuk. 2019;19(4):e184–e194.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2020 Issue Preview preliminary publication
Most read in this issue
- POEMS syndrome – a rare disease associated with monoclonal gammopathy and polyneuropathy: diagnosis and treatment
- Obinutuzumab in the treatment of a patient with Waldenström macroglobulinemia and rituximab intolerance: a case report
- A peripherally inserted central catheter is a safe means of ensuring long-term central venous access in patients with acute leukaemia – a single centre experience
- Pitfalls of treating chronic myeloid leukaemia with dasatinib – pulmonary arterial hypertension as a rare complication